The LymeX Diagnostics Prize: Phase 4 Breakthroughs
The LymeX Innovation Accelerator, a $10 million public-private partnership between HHS and the Cohen Foundation, is entering its final clinical validation phase in 2026.
Next-Gen Tools: The prize has accelerated the development of "high-dimensional" biological tools and AI-enabled methods to solve the "persistent symptom" puzzle.
Direct Detection: Several finalists are moving toward FDA submission for tests that detect the Borrelia bacteria itself (direct detection) rather than the body's immune response, which can be suppressed or delayed.
1회 조회